US regulator investigates tumour risk in children given Novartis gene therapy
The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis’ gene therapy Zolgensma. The Swiss drug maker earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its gene therapy drug used to treat patients less than two…
Full story
Read the full story at South China Morning Post ↗
Continue reading this story on South China Morning Post, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
